golexanolone

About Umecrine Cognition

Umecrine Cognition is a Stockholm-based biotech advancing a novel class of neurosteroid antagonists to treat cognitive disorders driven by neuroinflammation. Its lead asset, golexanolone, has shown positive Phase 2 results in hepatic encephalopathy and is being developed for PBC-related fatigue and cognitive dysfunction, representing a first-in-class approach. The company's strategy involves advancing its clinical pipeline and seeking partnerships for later-stage development and commercialization. With a focus on high-unmet-need neurological indications, Umecrine aims to address significant gaps in current therapeutic practice.

About Umecrine Cognition

Umecrine Cognition is a Stockholm-based biotech advancing a novel class of neurosteroid antagonists to treat cognitive disorders driven by neuroinflammation. Its lead asset, golexanolone, has shown positive Phase 2 results in hepatic encephalopathy and is being developed for PBC-related fatigue and cognitive dysfunction, representing a first-in-class approach. The company's strategy involves advancing its clinical pipeline and seeking partnerships for later-stage development and commercialization. With a focus on high-unmet-need neurological indications, Umecrine aims to address significant gaps in current therapeutic practice.

About Umecrine Cognition

Umecrine Cognition is a Stockholm-based biotech advancing a novel class of neurosteroid antagonists to treat cognitive disorders driven by neuroinflammation. Its lead asset, golexanolone, has shown positive Phase 2 results in hepatic encephalopathy and is being developed for PBC-related fatigue and cognitive dysfunction, representing a first-in-class approach. The company's strategy involves advancing its clinical pipeline and seeking partnerships for later-stage development and commercialization. With a focus on high-unmet-need neurological indications, Umecrine aims to address significant gaps in current therapeutic practice.

Therapeutic Areas